文献速递角膜与眼表疾病

局部1%环孢素在急性史蒂文斯-约翰逊综合征中的辅助作用评估:一项随机对照试验

Evaluation of adjuvant role of topical cyclosporine 1% in acute Stevens-Johnson syndrome: a randomised control trial.
PubMed 文献 · Br J Ophthalmol · 2024-12-17

该随机对照试验纳入44例(88眼)急性史蒂文斯-约翰逊综合征(SJS)患者,随机分为局部1%环孢素A(CsA)联合标准治疗组(44眼)和局部生理盐水联合标准治疗组(44眼),随访6个月。结果显示两组在6个月时各项眼表参数组间比较均无显著差异,且CsA组角膜角化和新生血管分级较基线恶化。结论认为局部CsA辅助治疗不优于标准治疗。

要点

  • 急性SJS患者中,局部1%CsA联合标准治疗在6个月时各项眼表参数与生理盐水联合标准治疗组无显著差异。
  • CsA组角膜角化分级从基线0.48±0.7恶化至6个月1.02±0.8(p=0.0015),角膜新生血管分级从1.07±1.2恶化至1.57±1.0(p=0.0412)。
  • 两组6个月时结膜充血、黏膜皮肤交界受累和睑板腺受累分级较基线均有显著改善。

核心结论

  • 在急性SJS患者中,局部CsA辅助治疗不优于标准治疗。

研究设计与样本

  • 随机对照试验,纳入44例(88眼)急性SJS患者,发病3个月内就诊,随机分为两组。

主要发现

  • CsA组平均年龄23.9±15.1岁,对照组26.0±18.7岁(p=0.6840)。
  • CsA组和对照组从发病到就诊的平均时间分别为17.0±14.0天和12.9±11.3天(p=0.1568)。
  • 6个月时,两组结膜充血(A组p=0.001;B组p=0.0001)、黏膜皮肤交界受累(A组p=0.001;B组p=0.0001)和睑板腺受累(A组p=0.0471;B组p=0.006)的平均严重程度分级均较基线显著改善。
  • 与基线相比,CsA组角膜角化分级(基线0.48±0.7;6个月1.02±0.8;p=0.0015)和角膜新生血管分级(基线1.07±1.2;6个月1.57±1.0;p=0.0412)在6个月时恶化。
  • 6个月时各项参数的组间比较均未显示显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the role of topical cyclosporine A 1% (CsA) as an adjuvant therapy in patients with acute Stevens-Johnson syndrome (SJS). METHODS: This is a randomised controlled trial in which 44 patients (88 eyes) with acute SJS, presenting within 3 months from the onset of the disease, were enrolled and randomised. Group A (n=44 eyes) patients received treatment with topical CsA 1% along with standard therapy consisting of topical corticosteroids, antibiotics and lubricants. Group B (n=44 eyes) patients received topical saline drops in combination with standard therapy. Various ocular surface parameters were assessed at baseline and the 6-month follow-up. RESULTS: The mean age of patients (years) was 23.9±15.1 in the CsA group and 26.0±18.7 in the control group (p=0.6840). The mean time from disease onset to presentation (days) was 17.0±14.0 and 12.9±11.3 in CsA and control groups, respectively (p=0.1568). At presentation, the mean grades of severity scores of various parameters were comparable. At 6 months, both groups showed a significant improvement in the mean severity grades of conjunctival hyperaemia (A, p=0.001; B, p=0.0001), mucocutaneous junction involvement (A, p=0.001; B, p=0.0001) and meibomian gland involvement (A, p=0.0471; B, p=0.006). Compared with baseline, the grades of corneal keratinisation (baseline, 0.48±0.7; 6 months, 1.02±0.8; p=0.0015) and neovascularisation (baseline, 1.07±1.2; 6 months, 1.57±1.0; p=0.0412) worsened after 6 months of CsA therapy. Intergroup comparison of grades of various parameters however did not reveal any significant difference at 6 months. CONCLUSIONS: Adjuvant treatment with topical CsA is not superior to standard therapy, in cases of acute SJS.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Sharma N, Venugopal R, Nagpal R, et al. Evaluation of adjuvant role of topical cyclosporine 1% in acute Stevens-Johnson syndrome: a randomised control trial. Br J Ophthalmol. 2024. PMID: 38802169. doi:10.1136/bjo-2023-324901

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。